This presentation from the Covid-19 Early Treatment Fund (a non-profit funding over a dozen trials) summarizes the data so far on Fluvoxamine. https://docs.goog

This presentation from the Covid-19 Early Treatment Fund (a non-profit funding over a dozen trials) summarizes the data so far on Fluvoxamine. https://docs.google.com/presentation/d/1u7resy2bGA1_HIgj6Nc7ahzeS7DrpOtkiK5ywhQhmpk/edit#slide=id.gaeebd14cc9_0_79 https://docs.google.com/presentation/d/1u7resy2bGA1_HIgj6Nc7... Executive Director Steve Kirsch wrote this post on the most promising early treatments and CETF feels Ivermectin and Fluvoximine are the two most promising which they are currently funding studies on. He's continuing to update this post almost daily. As of now, the data is still insufficient to be conclusive (which he highlights) but I appreciate they are sharing these kind of insights from the front lines, at least for those capable of understanding the nature of evolving research and the associated uncertainties. Of particular interest, he links to Washington University's large-population, remote trial of fluvoximine that's free and anyone can apply and participate from home. https://www.quora.com/What-is-the-current-treatment-for-Covid-19/answer/Steve-Kirsch https://www.quora.com/What-is-the-current-treatment-for-Covi...